Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
1 finding from 1 review
Participants admitted to hospital because of respiratory adverse events (treatment period) · adults with asthma
Bronchial thermoplasty leads to higher participants admitted to hospital because of respiratory adverse… compared with any active control (high certainty).
1 finding from 1 review
Participants admitted to hospital because of respiratory adverse events (post‐treatment period) · adults with asthma
Bronchial thermoplasty showed no clear difference in participants admitted to hospital because of respiratory adverse… compared with any active control (moderate certainty).
1 finding from 1 review
Adverse events (reported occurrence of: mild reduction in the visual acuity of the sound eye not requiring treatment; light sensitivity; skin, lid, or conjunctival irritation) Assessed at different time points (17 weeks or 2 years). · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Adverse effects: dry mouth · Adults with overactive bladder (OAB)
Anticholinergics may leads to higher adverse events: dry mouth compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes adverse events compared with placebo cigarettes (very low certainty).
1 finding from 1 review
Adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with active UC
Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events:urinary retention · Adults with overactive bladder (OAB)
Anticholinergics may leads to higher adverse events:urinary retention compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adults with overactive bladder (OAB)
Anticholinergics may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low